Evidence map›Paper›PMID 40012380›Full record

ReviewCardiovascular & hematological agents in medicinal chemistry2025

Oxidative Stress in Cardiovascular Diseases: Mechanisms and Exploring Advanced Therapies.

Dushyant Kamboj, Balram Choudhary, Gurvirender Singh, Nitish Kumar, Smita Narwal, Ashwani K Dhingra

Abstract readReview
PubMed Publisher
In one paragraph

Review in Cardiovascular & hematological agents in medicinal chemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Dushyant KambojInstitute of Pharmaceutical Sciences Kurukshetra University, Kurukshetra, 136119, Haryana, India.
Balram ChoudharyInstitute of Pharmaceutical Sciences Kurukshetra University, Kurukshetra, 136119, Haryana, India.
Gurvirender SinghInstitute of Pharmaceutical Sciences Kurukshetra University, Kurukshetra, 136119, Haryana, India.
Nitish KumarInstitute of Pharmaceutical Sciences Kurukshetra University, Kurukshetra, 136119, Haryana, India.
Smita NarwalGlobal Research Institute of Pharmacy, Radaur, Yamuna Nagar, 135133, Haryana, India.
Ashwani K DhingraGlobal Research Institute of Pharmacy, Radaur, Yamuna Nagar, 135133, Haryana, India.ORCID 0000-0001-7574-2971

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The recognition of oxidative stress as a factor influencing the development and progression of cardiovascular diseases (CVDs) is growing. By producing such reactive oxygen species (ROS) in diverse areas within cells, including mitochondria and Nicotinamide Adenine Dinucleotide Phosphate Hydrogen (NADPH)-oxidases, they end up causing damage through the oxidation of lipids, proteins, and DNA. ROS indicates the beginning of inflammatory responses and endothelial dysfunction, which are necessary to produce obstructions in blood vessels and decreased blood vessel function. The fact that oxidative stress plays a significant role in CVD development draws more attention to the need for novel therapies that aim to correct redox imbalances. Therefore, natural polyphenols and antioxidants like vitamin C or E have shown their efficacy in lowering levels of ROS and protecting against the damage caused by oxidative stress. Anyone attempting to cure CVDs should focus on improving the safety and efficacy of antioxidant treatments and identifying which patients will benefit from them the most. This paper discusses not only advanced treatments but also the role played by oxidative stress in such CVD as high blood pressure, hypercholesterolemia, and ischemic heart disease.

Indexed as

AntioxidantsCardiovascular DiseasesOxidative StressAnimalsHumansReactive Oxygen SpeciesAntioxidantsReactive Oxygen SpeciesantioxidantsCardiovascular diseases (CVDs)endothelial dysfunction.oxidative stressreactive oxygen species (ROS)redox imbalancetherapies

Identifiers

PMID40012380

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.